The National Comprehensive Cancer Network Oncology Research Program has funded two investigators from NCCN member institutions through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib in the treatment of epidermal growth factor receptor-positive non-small cell lung cancer.
The following studies were awarded funding through NCCN ORP:
Daniel Gomez, of MD Anderson Cancer Center, “Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR).”
Pasi Jänne, Dana-Farber/Brigham and Women’s Cancer Center, Massachusetts General Hospital Cancer Center, “A Phase II Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer.”
Submissions were peer reviewed by the NCCN Osimertinib Scientific Review Committee.
The funded concepts were selected based on several criteria, including scientific merit, existing data, and the types of studies necessary to further evaluate the efficacy ofosimertinib.
NCCN ORP draws upon the expertise of investigators at the NCCN member institutions and their affiliates to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. To date, this research model has received more than $60 million in research grants and supported more than 140 studies.